recombinant human coagulation factor VIII

Recombinant human coagulation factor VIII is a genetically engineered protein used to replace missing or deficient clotting factor VIII in individuals with hemophilia A. Produced using Chinese Hamster Ovary (CHO) or other mammalian cell lines via recombinant DNA technology[1][2][8], it is structurally and functionally similar to endogenous human Factor VIII. The drug acts as a cofactor for Factor IXa in the activation of Factor X in the intrinsic pathway of blood coagulation. Its primary indication is for the prevention and control of bleeding episodes in adults and children with hemophilia A[2][5][7]. Multiple brands exist based on different manufacturing processes and modifications (e.g., full-length vs B-domain deleted; PEGylated forms)[8]. It does not treat von Willebrand disease unless specifically formulated with von Willebrand Factor.

Brand names

AdvateAdynovateHelixateKogenateKovaltryNovoeightRecombinateAfstylaEloctateEsperoctJivi

Other names

antihemophilic factor (recombinant)recombinant antihemophilic factor